Lipoprotein(a): The Hidden Heart Risk Factor You Should Know About

Vannoni © 2026

Most of my patients know their cholesterol numbers. They can tell me their LDL, their HDL, maybe even their triglycerides. And, because I’ve been checking this for years, my patients also know about a little-known factor in the cholesterol equation called lipoprotein(a).

However, your friends and especially your first-degree relatives may not be aware of lipoprotein(a). In fact, until recently, even many doctors weren't routinely checking it. But that’s changing fast, and for good reason.

Lipoprotein(a), often written as Lp(a) and pronounced "L-P-little-a," is one of the most important cardiovascular risk factors that most people have never heard of. A new study published in March 2026 in the Journal of the American College of Cardiology reinforced just how significant it is, showing that elevated Lp(a) independently predicted a person's risk of developing atherosclerotic cardiovascular disease over 15 years, regardless of other test results. The updated ACC/AHA dyslipidemia guidelines now give a class 1 recommendation to measuring Lp(a) at least once in every adult's lifetime.

Here is what you need to know.

What Is Lipoprotein(a)?

Think of Lp(a) as a close cousin of LDL cholesterol, the "bad" cholesterol you've probably heard your doctor talk about. Like LDL, lipoprotein(a) is a particle that circulates in your blood and can deposit cholesterol into the walls of your arteries. But Lp(a) carries an extra protein attached to it called apolipoprotein(a), which makes it stickier, more inflammatory, and more likely to promote blood clots than regular LDL.

Here's the key difference: your LDL level is heavily influenced by your diet, exercise habits, and medications. Your Lp(a) level, on the other hand, is almost entirely determined by your genetics. You inherit it from your parents, and it stays relatively stable throughout your life. Diet and exercise have little to no effect on it. That's what makes it tricky, and that's why testing for it matters so much.

The Meyer Nutrition Plan combines a fully holistic approach to weight loss and wellbeing with highly personalized elite, concierge care. Created by renowned New York cardiologist and internist Mark Meyer, MD, FACP, FACC, our nutrition includes the most comprehensive health screening and management in Manhattan.
Book Appointment

Why Should You Care About Your Lp(a) Level?

• It is an independent risk factor for heart disease. Even if your LDL cholesterol, blood pressure, and other numbers look good, an elevated Lp(a) on its own raises your risk of heart attack, stroke, and narrowing of the arteries (atherosclerosis).

• It affects a lot of people. Roughly 20% of the global population, or about 1 in 5 people, has elevated Lp(a). Most of them don't know it because they've never been tested.

• It predicts risk over the long term. The new JACC study followed more than 11,000 people for nearly 15 years and found that those with Lp(a) above 50 mg/dL had a 24% higher risk of cardiovascular events, even after adjusting for coronary artery calcium scores and traditional risk factors.

• It is also linked to aortic valve disease. Elevated Lp(a) is associated with calcific aortic valve stenosis, a condition where the heart's aortic valve narrows and hardens over time.

• It is connected to blood clot risk. The apolipoprotein(a) component of Lp(a) has structural similarities to plasminogen, a protein involved in dissolving clots. This means elevated Lp(a) may interfere with your body's natural clot-dissolving process, raising the risk of dangerous clots.

• Standard cholesterol tests don't measure it. A routine lipid panel will not tell you your Lp(a) level. You need a separate, specific blood test, and you only need it done once since the level doesn't change much over time.

What Levels Are Considered Elevated?

Lp(a) can be reported in two different units depending on the lab, which sometimes causes confusion. Here is a simple guide:

• Desirable: Less than 30 mg/dL (or less than 75 nmol/L)

• Borderline elevated: 30 to 50 mg/dL (75 to 125 nmol/L)

• High risk: Greater than 50 mg/dL (or greater than 125 nmol/L)

The higher the number, the greater the concern. The recent JACC study used the 50 mg/dL threshold to define elevated Lp(a), and the new ACC/AHA guidelines have affirmed that levels above this cutoff are clinically significant and warrant attention.

Our Concierge Medicine Services
At Madison Avenue Cardiovascular & Concierge Medicine, Dr. Mark Meyer offers the most exclusive medical care through premier membership to our concierge medicine services.

What Can Be Done About It?

This is the part of the conversation where I have to be honest with my patients: right now, we don't have an FDA-approved medication that directly and effectively lowers Lp(a). But that doesn't mean we're powerless, and it certainly doesn't mean we should ignore the number.

Here is what we can do today:

• Get tested. The new guidelines recommend that every adult have their Lp(a) measured at least once. If you have a family history of early heart disease or if your LDL cholesterol has been hard to control, testing is especially important. Ask your doctor for the test at your next visit.

• Pursue aggressive LDL lowering. Since we can't yet lower Lp(a) directly with approved drugs, our best available strategy is to get LDL cholesterol as low as possible. The logic is straightforward: if your total burden of artery-clogging particles is high because of elevated Lp(a), reducing the LDL component of that burden gives your arteries the best chance of staying healthy. For patients with high Lp(a), I typically aim for more aggressive LDL targets, often well below 70 mg/dL.

• Optimize all other risk factors. Excellent lifestyle choices remain critical. Maintaining a heart-healthy diet, exercising regularly, not smoking, managing blood pressure, and controlling blood sugar all help reduce overall cardiovascular risk. While these steps won't lower your Lp(a), they reduce the cumulative load on your arteries.

• Consider PCSK9 inhibitors. These injectable medications (such as evolocumab and alirocumab), which are primarily used to lower LDL cholesterol, also reduce Lp(a) by about 20 to 25%. While that's a modest reduction, it can be a meaningful part of the treatment plan for some patients. While these medications may lower Lp(a) in some people, maybe 10-15%, it’s not known if lowering Lp(a) via this mechanism helps reduce cardiovascular risk. Nevertheless, it certainly doesn’t seem to hurt.

• Stay informed about emerging therapies. This is where the science gets exciting. Several medications specifically designed to lower Lp(a) by 80% to over 90% are currently in late-stage clinical trials. These include drugs like pelacarsen, olpasiran, and lepodisiran, which use RNA-based technology to block production of Lp(a) in the liver. Another promising drug, muvalaplin, is an oral medication that prevents the Lp(a) particle from assembling in the first place. Results from major phase 3 cardiovascular outcomes trials are expected in 2026 and 2027, and if they are positive, we may finally have purpose-built tools to treat this risk factor directly.

  Get The Meyer Nutrition Plan

So, What’s The Bottom Line For Me?

Lipoprotein(a) is a genetically determined, independent risk factor for heart disease that affects roughly one in five people. It doesn't show up on a standard cholesterol panel, it doesn't respond to diet or exercise, and until very recently, it hasn't gotten the attention it deserves. That is changing. The latest research confirms that elevated Lp(a) matters, the newest guidelines say you should be tested, and a new generation of targeted therapies is on the horizon.

If you haven't had your Lp(a) checked, I'd encourage you to bring it up with your doctor. It's a simple blood test, and for many patients, it fills in a missing piece of the puzzle when it comes to understanding their true cardiovascular risk.

Knowledge is the first step. And with Lp(a), knowledge is something we can act on right now.

Sources

1. Bhatia HS, Fan Y, Dharmavaram G, et al. "Use of Coronary Artery Calcium Scoring in Individuals with Elevated Lipoprotein(a): A Multicohort Study." Journal of the American College of Cardiology. 2026; Epub ahead of print. https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5067

2. Maxwell YL. "Lp(a) and CAC Levels Independently Predict Long-term ASCVD Risk." TCTMD. March 19, 2026. https://www.tctmd.com/news/lpa-and-cac-levels-independently-predict-long-term-ascvd-risk

3. American College of Cardiology. "Feature: Lipoprotein(a): An Independent Risk Factor for CV Disease." 2025. https://www.acc.org/latest-in-cardiology/articles/2025/12/01/01/feature-lipoprotein-a

4. Al-Dalakta A, Cho LS, Sarraju A. "Lipoprotein(a) in Clinical Practice: What Clinicians Need to Know." Cleveland Clinic Journal of Medicine. 2025;92(11):679-685. https://www.ccjm.org/content/92/11/679

5. Kolovou G, Katsiki N, Pavlou C. "Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?" Journal of Clinical Medicine. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12115060/

6. Kronenberg F. "Lipoprotein(a): From Causality to Treatment." Current Atherosclerosis Reports. 2024;26(3):75-82. https://pubmed.ncbi.nlm.nih.gov/38353915/

7. Shen X, et al. "Lepodisiran, a Long-Duration Small Interfering RNA Targeting Lipoprotein(a)." New England Journal of Medicine. 2025;392(17):1673-1683. https://pubmed.ncbi.nlm.nih.gov/40053039/

8. Managed Healthcare Executive. "New Therapies on the Way to Lower Lp(a), a Cardiovascular Risk Factor." March 2026. https://www.managedhealthcareexecutive.com/view/new-therapies-on-the-way-to-lower-lp-a-a-cardiovascular-risk-factor